ES2618352T3 - Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética - Google Patents
Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética Download PDFInfo
- Publication number
- ES2618352T3 ES2618352T3 ES07809581.7T ES07809581T ES2618352T3 ES 2618352 T3 ES2618352 T3 ES 2618352T3 ES 07809581 T ES07809581 T ES 07809581T ES 2618352 T3 ES2618352 T3 ES 2618352T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- benzoyl
- ylmethoxy
- indole
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
Un antagonista del receptor de prostaglandina D2 (receptor DP) para su uso en el tratamiento de la alopecia androgenética (AAG) en el cuero cabelludo de un sujeto.
Description
En otra realización, el antagonista del receptor DP es una variante de la estructura anterior, en la que el grupo ciclopentilo de la derecha arriba está sustituido por un grupo ciclohexilo. Cada uno de los sustituyentes enumerados 5 para la estructura anterior puede usarse para esta estructura que contiene ciclohexilo.
En otra realización, el antagonista del receptor DP tiene una de las siguientes estructuras:
7
En otras realizaciones, el antagonista del receptor DP es una sal no tóxica de uno de los compuestos anteriores.
En otras realizaciones, el antagonista del receptor DP se selecciona entre los siguientes compuestos: (1) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético,
- (2)
- ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (3) ácido 1-(4-((2R)-1,4-benzodioxan-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (4) ácido 1-(4-((2S)-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indolo-4-il-acético, (5) ácido 1-(4-((2S)-1-metilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il-acético, (6) ácido 1-(4-((2R)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (7) ácido 1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (8) ácido 1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (9) ácido 1-(4-((2S)-6-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (10) ácido 1-(4-((2S)-7-metoxi-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (11) ácido 1-(4-((2S)-4,7-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4ilacético, (12) ácido 1-(4-((2 S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (13) ácido 1-(4-((2S)-1-etilindolin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (14) ácido 1-(4-((2S)-4,8dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (15) ácido 1-(4-((2S)-5-metoxi4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (16) ácido 1-(4-((2S)-5-fluoro4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (17) ácido 1-(4-((2S)-2,3dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (18) ácido 1-(4-((2R)-2,3-dihidrobenzofuran-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (19) ácido 1-(4-((2S)-8-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (20) ácido 1-(4-((2R)-1,4-benzoxatian-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il-acético, (21) ácido 1-(4-((3S)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (22) ácido 1-(4-((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (23) ácido 1-(4-((3R)-5-fluoro2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (24) ácido 1-(4-((3R)-5-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (25) ácido 1-(4-((3R)-6-fluoro-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (26) ácido 1-(4-((3R)-7-metil-2,3dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-ilacético, (27) ácido 1-(4-((2R)-5-fluoro-1,4-benzodioxan-2ilmetoxi)benzoil)-2-metil-1H-indol-4-il-acético, (28) ácido 1-(4-((2S)-8-fluoro-1,4-benzodioxan-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il-acético, (29) ácido 1-(4-((3R)-7-fluoro-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4il-acético, (30) éster alílico del ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)acrílico, (31) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)acrílico, (32) ácido 3-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol4-il)propanoico, (33) éster bencílico del ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)oxiacético, (34) ácido (1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil1H-indol-4-il)oxiacético, (35) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (36) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-2-metil-1H-indol-4-carboxílico, (37) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4benzoxazin-2-ilmetoxi)benzoil)-1H-indol-4-il-acético, (38) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2ilmetoxi)benzoil)-1H-indol-4-il-acético, (39) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)2,3-dihidro-1H-indol-4-il-acético, (40) ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-2,3-dihidro-1H-indol-4-il-acético, (41) 2-(1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2metil-1H-indol-4-il)etanol, (42) 2-(1-(4-((2S)-4,6-dimetil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (43) 2-(1-(4-((2S)-6-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (44) 2-(1-(4-((2S)-7-fluoro-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1Hindol-4-il)etanol, (45) 2-(1-(4-((2S)-2,3-dihidrobenzofuran-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (46) 2-(1-(4((3R)-2,3-dihidrobenzofuran-3-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etanol, (47) N-metilsulfonil-( 1-(4-((2S)-4-metil3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (48) N-fenilsulfonil-(1-(4-((2S)-4metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)acetamida, (49) acetato de 2-(1-(4-((2S)4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)benzoil)-2-metil-1H-indol-4-il)etilo, (50) éster bencílico del ácido 1(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, (51) éster bencílico del ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético,
- (52)
- ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-2-metil-1H-indol-4-il-acético, y
- (53)
- ácido 1-(4-((2S)-4-metil-3,4-dihidro-2H-1,4-benzoxazin-2-ilmetoxi)-2-metilbenzoil)-1H-indol-4-il-acético o una sal no tóxica de los mismos.
En otras realizaciones, el antagonista del receptor DP tiene la estructura:
21
en la que
R.sup.1 representa hidroxi, alcoxi C1-6, o NR.sup.8R.sup.9, en la que cada uno de R.sup.8 y R.sup.9 representa independientemente un átomo de hidrógeno, alquilo C1-6, o SO.sub.2R.sup.13, en la que R.sup.13 representa alquilo C1-6, un anillo carbocíclico saturado o insaturado C3-15 o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno; R.sup.2 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, amino, trihalometilo, ciano, hidroxi, bencilo, o 4-metoxibencilo; R.sup.3 representa un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, un átomo de halógeno, trihalometilo, ciano, o hidroxi; cada uno de R.sup.4 y R.sup.5 representa independientemente un átomo de hidrógeno, alquilo C1-6, alcoxi C1-6, alcoxialquilo C2-6, un átomo de halógeno, nitro, amino, trihalometilo, ciano, o hidroxi; D representa un enlace sencillo, alquileno C1-6, alquenileno C2-6, u oxialquileno C1-6; en --G--R.sup.6,
1) G representa un enlace sencillo, alquileno C1-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, alquenileno C2-6 que puede estar sustituido con 1 a 2 átomos de oxígeno y/o átomos de azufre, en la que el alquileno y el alquenileno pueden estar sustituidos con hidroxi o alcoxi C1-4, --C(O)NH--, --NHC(O)--, -SO.sub.2NH--,-NHSO.sub.2--, o diazo; R.sup.6 representa un anillo carbocíclico saturado o insaturado C3-15, o un anillo heterocíclico de 4 a 15 miembros que contiene de 1 a 5 átomos de nitrógeno, átomos de azufre y/o átomos de oxígeno, en la que el anillo puede estar sustituido con 1 a 5 sustituyentes seleccionados entre alquilo C1-6, alcoxi C1-10, alcoxialquilo C2-6, un átomo de halógeno, hidroxi, trihalometilo, nitro, amino, fenilo, fenoxi, oxo, acilo C2-6, alcanosulfonilo C1-6 y ciano,
2) G y R.sup.6 se toman juntos para representar
- (i)
- alquilo C1-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre;
- (ii)
- alquenilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre; o
(iii) alquinilo C2-15 que puede estar sustituido con 1 a 5 átomos de oxígeno y/o átomos de azufre, en la que el alquilo, el alquenilo y el alquinilo pueden estar sustituidos con 1 a 12 sustituyentes seleccionados entre alcoxi C1-6, un átomo de halógeno, hidroxi, ciano, oxo y NR.sup.11R.sup.12, en la que cada uno de R.sup.11 y R.sup.12 representa independientemente un átomo de hidrógeno, alquilo C1-6, alquenilo C2-6, fenilo, benzoílo, naftilo, fenilo sustituido con alquilo C1-6, o alquilo C1-6 sustituido con fenilo o ciano; n representa de 1 a 3; m representa de 1 a 3; i representa de 1 a 4; y
22
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81404106P | 2006-06-16 | 2006-06-16 | |
US814041P | 2006-06-16 | ||
US84516106P | 2006-09-18 | 2006-09-18 | |
US845161P | 2006-09-18 | ||
PCT/US2007/014031 WO2007149312A2 (en) | 2006-06-16 | 2007-06-15 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2618352T3 true ES2618352T3 (es) | 2017-06-21 |
Family
ID=38833999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07809581.7T Active ES2618352T3 (es) | 2006-06-16 | 2007-06-15 | Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética |
Country Status (10)
Country | Link |
---|---|
US (3) | US9254293B2 (es) |
EP (2) | EP2037967B1 (es) |
CY (1) | CY1118737T1 (es) |
DK (1) | DK2037967T3 (es) |
ES (1) | ES2618352T3 (es) |
HU (1) | HUE030850T2 (es) |
PL (1) | PL2037967T3 (es) |
PT (1) | PT2037967T (es) |
SI (1) | SI2037967T1 (es) |
WO (1) | WO2007149312A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060241696A1 (en) * | 2005-04-26 | 2006-10-26 | Stjepan Krco | Method of limiting hair loss and promoting hair growth |
US20150072963A1 (en) * | 2006-06-16 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
US8455547B2 (en) | 2008-02-05 | 2013-06-04 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
US8748177B2 (en) * | 2008-09-30 | 2014-06-10 | The Hospital For Sick Children | Compositions for proliferation of cells and related methods |
CA2819859A1 (en) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
CA2867901A1 (en) * | 2012-03-21 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
FR3000397A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee |
FR3000398A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee |
FR3000396A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de doxycycline pour le traitement de la rosacee |
FR3000394A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de metronidazole pour le traitement de la rosacee |
FR3000395A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee |
FR3000399B1 (fr) * | 2012-12-31 | 2015-03-27 | Galderma Res & Dev | Utilisation topique du laropiprant pour le traitement de la rosacee |
US9797903B2 (en) | 2012-10-24 | 2017-10-24 | Winthrop-University Hospital | Non-invasive biomarker to identify subject at risk of preterm delivery |
WO2014079805A1 (en) * | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
WO2014079803A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Bicyclosubstituted pyrazole compounds for treating hairloss |
WO2014079806A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrimidine compounds for treating hairloss |
US10080771B2 (en) * | 2015-01-28 | 2018-09-25 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generation of human epithelial stem cells |
KR20180031019A (ko) * | 2015-07-30 | 2018-03-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Pgd2에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 dp―2 유전자의 단일 뉴클레오티드 다형성 대립유전자 |
WO2019050480A1 (en) * | 2017-09-07 | 2019-03-14 | Agency For Science, Technology And Research | METHODS FOR SCREENING AGENTS FOR CONTROLLING HAIR / HAIR PUSH OR HAIR / HAIR CYCLE |
AU2018331400A1 (en) | 2017-09-13 | 2020-04-02 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
KR101857408B1 (ko) * | 2018-02-28 | 2018-05-14 | 경북대학교 산학협력단 | 탈모 예방 또는 치료용 조성물 |
US10835538B2 (en) * | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
EP3934615A4 (en) * | 2019-03-08 | 2023-01-25 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TREATMENT OF ACNE |
CN110278919A (zh) * | 2019-07-30 | 2019-09-27 | 罗洋 | 一种构建蠕形螨致玫瑰痤疮样皮损动物模型的方法 |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
KR20230031322A (ko) * | 2020-06-27 | 2023-03-07 | 크레센타 바이오사이언시즈 | 세포 물질대사를 조정하는 화합물의 조성물 및 사용 방법 |
WO2023060320A1 (en) * | 2021-10-15 | 2023-04-20 | Bod Science Limited | Topical protein based formulation |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI872553A (fi) * | 1986-06-09 | 1987-12-10 | American Cyanamid Co | Medium foer laekemedel foer lokalt bruk. |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
CN1179945C (zh) | 2000-03-09 | 2004-12-15 | 小野药品工业株式会社 | 吲哚衍生物、其制备方法及用途 |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
FR2812192B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
CA2429579A1 (en) | 2000-11-22 | 2002-05-30 | Trillium Therapeutics Inc. | Truncated cd200 |
US7638598B2 (en) | 2001-04-06 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | ErbB interface peptidomimetics and methods of use thereof |
EP1424335A4 (en) | 2001-09-07 | 2005-11-16 | Ono Pharmaceutical Co | INDOLE DERIVATIVES |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
EP1482973B1 (en) | 2002-03-15 | 2009-08-19 | Schering Corporation | Methods of modulating cd200 receptors |
BR0308518A (pt) | 2002-03-19 | 2005-02-22 | Ono Pharmaceutical Co | Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
WO2004004661A2 (en) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
ES2263015T3 (es) | 2002-10-21 | 2006-12-01 | Warner-Lambert Company Llc | Derivados de tetrahidroquinolina como antagonistas de crth2. |
FI116400B (fi) | 2002-11-19 | 2005-11-15 | Metso Paper Inc | Paperi- tai kartonkikoneen puristinosa |
JP2006512396A (ja) | 2002-12-27 | 2006-04-13 | シェーリング コーポレイション | 免疫寛容を誘導および維持する方法 |
EP1435356A1 (en) | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
NZ545934A (en) * | 2003-09-17 | 2009-05-31 | Ono Pharmaceutical Co | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
US20050112075A1 (en) * | 2003-11-25 | 2005-05-26 | Hwang Cheng S. | Reduction of hair growth |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
CN1930162B (zh) | 2004-03-11 | 2010-06-16 | 埃科特莱茵药品有限公司 | 四氢吡啶并吲哚衍生物 |
AR048528A1 (es) | 2004-04-07 | 2006-05-03 | Millennium Pharm Inc | Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen. |
CA2563707A1 (en) | 2004-04-20 | 2005-11-03 | Pfizer Inc. | Method of treating neuropathic pain using a crth2 receptor antagonsit |
CA2581338A1 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
KR101437799B1 (ko) | 2004-12-29 | 2014-09-11 | 가부시키가이샤 아루떼꾸 우에노 | 두피 및 모발 치료용 조성물 및 치료 방법 |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
WO2006105109A2 (en) | 2005-03-29 | 2006-10-05 | The Trustees Of The University Of Pennsylvania | Methods for generating new hair follicles, treating baldness, and hair removal |
EP1882937B1 (en) | 2005-05-17 | 2012-02-22 | Taiho Pharmaceutical Co., Ltd. | Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease |
RU2333763C2 (ru) | 2006-02-27 | 2008-09-20 | Дмитрий Николаевич Мясников | Средство для профилактики и лечения андрогенной алопеции, очагового и себорейного облысения, жирной и густой себореи волосистой части головы, перхоти и способ его получения |
GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
DK2046740T3 (da) | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
CA2765706A1 (en) | 2009-06-17 | 2010-12-23 | Aderans Research Institute, Inc. | Methods and compositions for increasing trichogenic potency of dermal cells |
SG177736A1 (en) | 2009-07-31 | 2012-02-28 | Panmira Pharmaceuticals Llc | Dermal formulations of dp2 receptor antagonists |
US8771765B1 (en) | 2009-12-22 | 2014-07-08 | Ailin Fernandez | Method and composition for treatment of hair loss |
US20100172865A1 (en) | 2010-03-18 | 2010-07-08 | Shantha Totada R | Methods of enhancing hair growth |
CA2819859A1 (en) | 2010-12-06 | 2012-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
CA2867901A1 (en) | 2012-03-21 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
-
2007
- 2007-06-15 EP EP07809581.7A patent/EP2037967B1/en active Active
- 2007-06-15 DK DK07809581.7T patent/DK2037967T3/en active
- 2007-06-15 PL PL07809581T patent/PL2037967T3/pl unknown
- 2007-06-15 EP EP16196670.0A patent/EP3175856A1/en active Pending
- 2007-06-15 HU HUE07809581A patent/HUE030850T2/en unknown
- 2007-06-15 SI SI200731896A patent/SI2037967T1/sl unknown
- 2007-06-15 ES ES07809581.7T patent/ES2618352T3/es active Active
- 2007-06-15 WO PCT/US2007/014031 patent/WO2007149312A2/en active Application Filing
- 2007-06-15 US US12/303,998 patent/US9254293B2/en active Active
- 2007-06-15 PT PT78095817T patent/PT2037967T/pt unknown
-
2015
- 2015-08-24 US US14/833,470 patent/US9889082B2/en active Active
-
2017
- 2017-03-06 CY CY20171100287T patent/CY1118737T1/el unknown
-
2018
- 2018-02-12 US US15/894,691 patent/US10849841B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9254293B2 (en) | 2016-02-09 |
PT2037967T (pt) | 2017-03-14 |
HUE030850T2 (en) | 2017-06-28 |
US20160346186A1 (en) | 2016-12-01 |
WO2007149312A3 (en) | 2009-04-02 |
PL2037967T3 (pl) | 2017-07-31 |
EP3175856A1 (en) | 2017-06-07 |
US20190380942A1 (en) | 2019-12-19 |
US20110021599A1 (en) | 2011-01-27 |
EP2037967A2 (en) | 2009-03-25 |
DK2037967T3 (en) | 2017-03-13 |
US10849841B2 (en) | 2020-12-01 |
SI2037967T1 (sl) | 2017-04-26 |
CY1118737T1 (el) | 2018-03-07 |
US9889082B2 (en) | 2018-02-13 |
EP2037967B1 (en) | 2016-12-07 |
EP2037967A4 (en) | 2010-07-07 |
WO2007149312A2 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2618352T3 (es) | Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética | |
RU2404979C2 (ru) | 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ | |
AR058401A1 (es) | Pirimidinas sustituidas con sulfoximinas proceso para su produccion y uso de las mismas como farmacos | |
AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
AR032624A1 (es) | Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica | |
AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
RU2004132204A (ru) | Имидазоконденсированные соединения | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
AR039403A1 (es) | Derivados de acil-4-carboxifenilurea y su uso como antidiabetico | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
AR050430A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
RU2008142600A (ru) | Органическое соединение | |
AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
AR078786A1 (es) | Derivados de la cromenona | |
AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
AR020551A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos. | |
AR068734A1 (es) | Esteroides con actividad agonista del receptor de glucocorticoides | |
CO5150225A1 (es) | Derivados del tetrahidropirano y su uso como agentes terapeuticos | |
PE20081657A1 (es) | Derivados de ftalazina como antagonistas de los receptores de histamina h1 | |
AR045378A1 (es) | Analogos de quinazolina como inhibidores del receptor de tirosin quinasas | |
RU2009136343A (ru) | Макроциклическое соединение |